Comparing SG&A Expenses: Eli Lilly and Company vs Madrigal Pharmaceuticals, Inc. Trends and Insights

Eli Lilly vs. Madrigal: A Decade of SG&A Insights

__timestampEli Lilly and CompanyMadrigal Pharmaceuticals, Inc.
Wednesday, January 1, 2014662080000015746000
Thursday, January 1, 2015653300000013392000
Friday, January 1, 201664520000009290000
Sunday, January 1, 201765881000007672000
Monday, January 1, 2018597510000015293000
Tuesday, January 1, 2019621380000022648000
Wednesday, January 1, 2020612120000021864000
Friday, January 1, 2021643160000037318000
Saturday, January 1, 2022644040000048130000
Sunday, January 1, 20236941200000108146000
Monday, January 1, 20248593800000
Loading chart...

Data in motion

A Decade of SG&A Trends: Eli Lilly vs. Madrigal Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Eli Lilly and Company has consistently demonstrated robust financial management, with Selling, General, and Administrative (SG&A) expenses averaging around $6.4 billion annually. This reflects a stable investment in operational efficiency and market presence.

In contrast, Madrigal Pharmaceuticals, Inc., a smaller player, has shown a dynamic growth trajectory. From 2014 to 2023, Madrigal's SG&A expenses surged by over 580%, indicating aggressive expansion and increased market activities. This growth, from approximately $15 million to $108 million, underscores Madrigal's strategic push to enhance its competitive edge.

These trends highlight the contrasting strategies of a pharmaceutical giant and an emerging contender, offering valuable insights into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025